BACKGROUND: Subclinical hypothyroidism (SCH) is not a rare condition in females, the elderly, or patients with chronic kidney disease (CKD). Even though previous studies have demonstrated that thyroid hormone replacement therapy (THRT) improves cardiac function and dyslipidemia in patients with SCH, it remains unclear as to whether THRT can improve renal function in CKD patients with SCH. This study investigated the impact of THRT on changes in estimated glomerular filtration rates (eGFR) in this patient population. METHODS: A total of 113 CKD patients with SCH who were treated with L-thyroxine and had eGFR available for at least 24 months before and after THRT were enrolled between January 2005 and December 2011. A linear mixed model was used to compare patients' clinical and biochemical parameters at various time points. The slope of the decline in eGFR over time, both before and after THRT, was also calculated and compared using a linear mixed model. RESULTS: The mean age of the study participants was 63.2±12.7 years, and 36 patients (31.9%) were men. The mean follow-up duration before and after THRT was 28.6±4.5 and 30.6±6.4 months respectively. After 24 months of THRT, serum thyrotropin (TSH) levels were significantly reduced-8.86±0.49 versus 1.41±0.73 μIU/mL, p<0.001-but there were no significant changes in triiodothyronine and free thyroxine concentrations. Serum albumin, calcium, phosphate, cholesterol, and triglyceride levels were also comparable before and after THRT. The rates of decline in eGFR were significantly attenuated by THRT (-4.31±0.51 vs.-1.08±0.36 [mL/min]/[year·1.73 m²], p<0.001), even after adjustment for age, sex, diabetes, mean arterial pressure, and serum albumin, cholesterol, and triglyceride concentrations (p<0.001). CONCLUSION: THRT attenuated the rate of decline in renal function in CKD patients with SCH, suggesting that THRT may delay reaching end-stage renal disease in these patients.
BACKGROUND:Subclinical hypothyroidism (SCH) is not a rare condition in females, the elderly, or patients with chronic kidney disease (CKD). Even though previous studies have demonstrated that thyroid hormone replacement therapy (THRT) improves cardiac function and dyslipidemia in patients with SCH, it remains unclear as to whether THRT can improve renal function in CKDpatients with SCH. This study investigated the impact of THRT on changes in estimated glomerular filtration rates (eGFR) in this patient population. METHODS: A total of 113 CKDpatients with SCH who were treated with L-thyroxine and had eGFR available for at least 24 months before and after THRT were enrolled between January 2005 and December 2011. A linear mixed model was used to compare patients' clinical and biochemical parameters at various time points. The slope of the decline in eGFR over time, both before and after THRT, was also calculated and compared using a linear mixed model. RESULTS: The mean age of the study participants was 63.2±12.7 years, and 36 patients (31.9%) were men. The mean follow-up duration before and after THRT was 28.6±4.5 and 30.6±6.4 months respectively. After 24 months of THRT, serum thyrotropin (TSH) levels were significantly reduced-8.86±0.49 versus 1.41±0.73 μIU/mL, p<0.001-but there were no significant changes in triiodothyronine and free thyroxine concentrations. Serum albumin, calcium, phosphate, cholesterol, and triglyceride levels were also comparable before and after THRT. The rates of decline in eGFR were significantly attenuated by THRT (-4.31±0.51 vs.-1.08±0.36 [mL/min]/[year·1.73 m²], p<0.001), even after adjustment for age, sex, diabetes, mean arterial pressure, and serum albumin, cholesterol, and triglyceride concentrations (p<0.001). CONCLUSION:THRT attenuated the rate of decline in renal function in CKDpatients with SCH, suggesting that THRT may delay reaching end-stage renal disease in these patients.
Authors: J Lekakis; C Papamichael; M Alevizaki; G Piperingos; P Marafelia; J Mantzos; S Stamatelopoulos; D A Koutras Journal: Thyroid Date: 1997-06 Impact factor: 6.568
Authors: Dong Ho Shin; Mi Jung Lee; Seung Jun Kim; Hyung Jung Oh; Hyoung Rae Kim; Jae Hyun Han; Hyang Mo Koo; Fa Mee Doh; Jung Tak Park; Seung Hyeok Han; Tae-Hyun Yoo; Shin-Wook Kang Journal: J Clin Endocrinol Metab Date: 2012-06-20 Impact factor: 5.958
Authors: W F Crowley; E C Ridgway; E W Bough; G S Francis; G H Daniels; I A Kourides; G S Myers; F Maloof Journal: N Engl J Med Date: 1977-01-06 Impact factor: 91.245
Authors: Martin I Surks; Eduardo Ortiz; Gilbert H Daniels; Clark T Sawin; Nananda F Col; Rhoda H Cobin; Jayne A Franklyn; Jerome M Hershman; Kenneth D Burman; Margo A Denke; Colum Gorman; Richard S Cooper; Neil J Weissman Journal: JAMA Date: 2004-01-14 Impact factor: 56.272
Authors: Christiaan L Meuwese; Olaf M Dekkers; Peter Stenvinkel; Friedo W Dekker; Juan J Carrero Journal: Nat Rev Nephrol Date: 2013-09-03 Impact factor: 28.314
Authors: Christiaan L Meuwese; Merel van Diepen; Anne R Cappola; Mark J Sarnak; Michael G Shlipak; Douglas C Bauer; Linda P Fried; Massimo Iacoviello; Bert Vaes; Jean Degryse; Kay-Tee Khaw; Robert N Luben; Bjørn O Åsvold; Trine Bjøro; Lars J Vatten; Anton J M de Craen; Stella Trompet; Giorgio Iervasi; Sabrina Molinaro; Graziano Ceresini; Luigi Ferrucci; Robin P F Dullaart; Stephan J L Bakker; J Wouter Jukema; Patricia M Kearney; David J Stott; Robin P Peeters; Oscar H Franco; Henry Völzke; John P Walsh; Alexandra Bremner; José A Sgarbi; Rui M B Maciel; Misa Imaizumi; Waka Ohishi; Friedo W Dekker; Nicolas Rodondi; Jacobijn Gussekloo; Wendy P J den Elzen Journal: Nephrol Dial Transplant Date: 2019-04-01 Impact factor: 5.992
Authors: Connie M Rhee; Gregory A Brent; Csaba P Kovesdy; Offie P Soldin; Danh Nguyen; Matthew J Budoff; Steven M Brunelli; Kamyar Kalantar-Zadeh Journal: Nephrol Dial Transplant Date: 2014-02-25 Impact factor: 5.992